About Wren Laboratories
Focused on molecular liquid biopsy cancer diagnostics since 2014
Wren Laboratories is a CLIA, CAP, NYSDOH, and ISO15189-certified clinical testing and R&D laboratory established in 2014. The laboratory was founded as a commercial extension of their decades of academic and medical research into non-invasive liquid biopsy tests for a wide variety of cancers and other diseases that can be detected and better understood via molecular biomarkers such as mRNA.
Our Mission: Transform cancer diagnostics through innovative liquid biopsy mRNA technology.
At Wren Labs, our mission is to pioneer innovative in-vitro diagnostics using machine learning and liquid biopsy-RNA technologies. We aim to enhance the detection of minimal residual disease, predict and monitor cancer response to therapies, and improve disease prognosis and outcomes.
OUR VALUES
Focused on Science, Innovation, and Collaboration
Be it blood or saliva, our molecular cancer diagnostics provide actionable disease information in real time.
Committed to Science
We are committed to scientific discipline and harnessing the benefits of rigorously applied molecular science.
A Pioneering Spirit
To combat cancer effectively, an innovative approach is essential, leveraging cutting-edge applications and techniques.
True Collaborators
We know managing cancer requires inspired teamwork. We are open, connected, and fully collaborative.
Excellence in Execution
We seek excellence across all phases of our operations: research, clinical testing, and data analysis.
Focused on Success
The stakes could not be higher in our space; our principal focus is to positively impact the lives of cancer patients.
Credentials & Licenses
CLIA certification #: 07D2081388
CAP accreditation #: 8640840
NYSDOH-CLEP license #: PFI: 9138
Connecticut license #: CL-996
California license #: CDS-00800634
ISO15189 certificate #: 8640840
ABOUT OUR LAB
Our CAP-accredited and CLIA-certified Clinical Lab
All the molecular research, testing, and analysis we do is conducted at our CAP-accredited and CLIA-certified clinical laboratory in Branford, CT. The College of American Pathologists (CAP) accredits laboratories that meet their standards for quality of services using established performance standards. CLIA, or Clinical Laboratory Improvement Amendments, regulates laboratory testing and requires clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before being able to accept human samples for diagnostic testing.
Most of the liquid biopsy tests we perform are based on real-time quantitative polymerase chain reaction (qPCR) methodology using RNA isolated from peripheral blood or saliva. qPCR is known for sensitive, specific, and reproducible gene expression measurement. Within our lab, we have optimized and standardized the testing processes utilized by our experienced and highly-trained technicians, who adhere to extensive quality control procedures to ensure reproducible and reliable testing results at every stage of our testing process:
RNA quantity and quality:
There must be a sufficient quantity of purified RNA to perform all qPCR reactions. The RNA must also meet acceptance criteria for purity, which includes testing for the presence of excess genomic DNA, which can interfere with gene expression measurement.
Gene-specific measurement ranges:
The measured quantity of each gene product must fall within established ranges.
Efficiency of qPCR:
The output of the polymerase chain reaction process, which doubles the target material every cycle, must fall within defined limits.
Accuracy & Precision:
Accuracy is the degree to which measurements equal the actual quantity in the absence of variability. Precision is the random variation from true quantity. Each of the genes tested must be within established accuracy and precision specifications.
STRATEGY & PIPELINE
Our Scientific Strategy and Forward Focus
Our scientific strategy involves identifying a series of gene signatures that enable us to categorize the state of a disease, primarily cancer at this stage. This information can be utilized for timely disease recurrence identification or to assess the effectiveness of therapy.
